Bizarre Patents
A helium-filled sun shade for protecting individuals engaged in outdoor activities.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7771996 | FVII or FVIIa variants Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa. ... | 08/10/2010 |
| 7408027 | Tools for the diagnosis and treatment of Alzheimer's disease The invention relates to epitopes of the tau protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau pro... | 08/05/2008 |
| 7311913 | Methods of treating thrombotic diseases with von Willebrand factor specific antibodies Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor. ... | 12/25/2007 |
| 7291333 | Blockade of protein C activation reduces microvascular surgical blood loss A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma. ... | 11/06/2007 |
| 7273925 | Methods and products for regulating lectin complement pathway associated complement activation The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are ... | 09/25/2007 |
| 7241578 | Immunoassay method/equipment, biological component measurable toilet, anti-albumin monoclonal antibody, cell strain producing the same, and albumin detection kit The immunoassay method of this invention measures the content of a subject substance in a sample. The method includes the steps of: (a) preparing a mixed solution by mixing the sample and an antibody solution including a first monoclonal antibody and a second monocl... | 07/10/2007 |
| 7189700 | Anti-chrondrosarcoma compounds The invention provides inhibitors of chondrosarcoma cell growth that are useful as anti-cancer and anti-tumor agents. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases and that can inhibit th... | 03/13/2007 |
| 7186693 | Metalloproteinase inhibitors for wound healing The invention provides inhibitors of matrix metalloproteinases that are useful for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention ... | 03/06/2007 |
| 7183108 | Selection and uses of lactic acid bacteria strains modulating non-specific immunity The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fe... | 02/27/2007 |
| 7094754 | Anti-aging and wound healing compounds The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metallop... | 08/22/2006 |
| 7071164 | Anti-cancer and wound healing compounds The invention provides inhibitors of matrix metalloproteinases that are useful as anti-tumor agents and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inh... | 07/04/2006 |
| 7030129 | Method of reducing and treating UVB-induced immunosuppression Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs. ... | 04/18/2006 |
| 7022521 | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical... | 04/04/2006 |
| 6998468 | Anti-C2/C2a inhibitors of complement activation The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin ... | 02/14/2006 |
| 6989241 | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor A highly specific monoclonal antibody, produced by a hybridoma cell has been found. A new assay, highly specific for activated protein C (APC) has been developed which will permit rapid determination of APC levels in clinical situations. ... | 01/24/2006 |
| 6969516 | Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration A method is described comprising the combined administration of a novel composition comprising serum complement proteins with complement-fixing antibodies to induce transient disruption of myelin and/or demyelination. The antibodies specifically bind to one or more ... | 11/29/2005 |
| 6964854 | Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. ... | 11/15/2005 |
| 6960472 | Monoclonal antibodies against N-Terminus proBNP Monoclonal antibodies having high affinity for N-terminus pro brain natriuretic peptide (NT-proBNP) are described. The monoclonal antibodies are prepared against a synthetic peptide having the Sequence ID No. 1. Specifically, the monoclonal antibodies described are ... | 11/01/2005 |
| 6956107 | Inhibitors of complement activation The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including ... | 10/18/2005 |
| 6911178 | Rh blood group antigen compositions and methods of use Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human ... | 06/28/2005 |
| 6906036 | Anti-aging and wound healing compounds The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metallop... | 06/14/2005 |
| 6893831 | Immunoassay of PIVKA-II The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related subs... | 05/17/2005 |
| 6855508 | ELISA for VEGF The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEG... | 02/15/2005 |
| 6838250 | Immunoassay for C-reactive protein The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monocl... | 01/04/2005 |
| 6793920 | Antithrombotic agent and anti-von willebrand factor monoclonal antibody A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human pl... | 09/21/2004 |
| 6733980 | Diagnostic method for detection of molecular forms of eosinophilic cationic protein (ISO-ECPS) Diagnostic methods comprise measuring specifically the level of at least one iso-eosinophilic cationic protein (iso-ECP) in a sample from an individual to be diagnosed, and comparing the measured level of the iso-ECP with a predetermined level of the iso-ECP. The is... | 05/11/2004 |
| 6544786 | Method and vector for producing and transferring trans-spliced peptides A method for trans-splicing peptides is provided. In the method, at least two extein peptides are provided, or are synthesized by recombinant methods, the extein peptides having co-reacting portions of a split intein attached thereto, so that the peptides... | 04/08/2003 |
| 6534058 | Anti-C5 monoclonal antibodies The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rej... | 03/18/2003 |
| 6524862 | Complex of lipoprotein with hemoglobin or hemoglobin analog A selective complex of a lipoprotein with hemoglobin or a hemoglobin analogue. A method of assaying hemoglobin or a hemoglobin analogue in a sample, comprising reacting the sample with a lipoprotein which is capable of selectively forming a complex with h... | 02/25/2003 |
| 6485970 | Immunointeractive antibody The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides... | 11/26/2002 |
| 6451599 | Monoclonal antibodies reactive with fibrin (ogen) degradation products generated by matrix metalloproteinases The invention provides monoclonal antibodies which are reactive with fibrin(ogen) degradation products (FDPS) generated by matrix metalloproteinases (MMPs), such as MMP-3, MMP-7, and membrane-type 1, MT1-MMP proteolysis of fibrinogen and cross-linked fibr... | 09/17/2002 |
| 6451545 | Monoclonal antibody specific to anti-human fibrin monomer, process for producing the same, hybridomas, and immunoassay method Provided are a monoclonal antibody making it possible to detect a native fibrin monomer, which is produced at the initial state of blood coagulation, and soluble fibrin; a hybridoma; and an immunoassay for detecting the initial stage of blood coagulation ... | 09/17/2002 |
| 6391635 | Monoclonal human natural antibodies Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.... | 05/21/2002 |
| 6391568 | Method for determining platelet reactivity in a whole blood sample The present invention provides a method for the quantification and assessment of platelet activation in whole blood samples and monitoring of antiplatelet pharmacologic agents. The method for quantifying platelet activation includes exposing platelets to ... | 05/21/2002 |
| 6376242 | Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pha... | 04/23/2002 |
| 6365155 | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof are used in pharmaceutical preparations and in diagnosis. Cells which express these antibodies, antibody fragments, mixtures or derivatives thereof are also disclos... | 04/02/2002 |
| 6355245 | C5-specific antibodies for the treatment of inflammatory diseases The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other path... | 03/12/2002 |
| 6306653 | Detection and treatment of breast disease An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa... | 10/23/2001 |
| 6280731 | Antithrombotic agent and anti-von willebrand factor monoclonal antibody A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) ... | 08/28/2001 |
| 6248546 | Assay of IGFBP complex A method of assaying the growth hormone status of an individual by immuno-assay for the 150 KDa Insulin-like Growth Factor ternary complex (IGF/IGFBP-3/ALS). Alternatively, a binary complex may be assayed. The method involves capturing the IGFBP complex w... | 06/19/2001 |
